Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BioNTech SE    BNTX

BIONTECH SE

(BNTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/06/2020 07/07/2020 07/08/2020 07/09/2020 07/10/2020 Date
65.51(c) 69.34(c) 67.56(c) 65.61(c) 70.36(c) Last
1 649 445 2 264 397 1 449 603 1 186 732 2 874 259 Volume
+3.54% +5.85% -2.57% -2.89% +7.24% Change
More quotes
Financials
Sales 2020 152 M 172 M 172 M
Net income 2020 -173 M -195 M -195 M
Net cash position 2020 458 M 518 M 518 M
P/E ratio 2020 -70,3x
Yield 2020 -
Sales 2021 570 M 646 M 646 M
Net income 2021 222 M 251 M 251 M
Net cash position 2021 1 195 M 1 354 M 1 354 M
P/E ratio 2021 108x
Yield 2021 -
Capitalization 14 125 M 15 956 M 15 999 M
EV / Sales 2020 89,9x
EV / Sales 2021 22,7x
Nbr of Employees 1 400
Free-Float 95,0%
More Financials
Company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer... 
More about the company
Surperformance© ratings of BioNTech SE
Trading Rating : Investor Rating :
More Ratings
Latest news on BIONTECH SE
07:28aPfizer, BioNTech's Covid-19 Vaccine Candidates Get Fast-Track Designation
DJ
07:23aPfizer, BioNTech's coronavirus vaccine candidates get FDA's 'fast track' stat..
RE
06:54aPfizer, BioNTech's coronavirus vaccines get FDA's 'fast track' status
RE
06:46aPfizer and BioNTech Granted FDA Fast Track Designation for Two Investigationa..
GL
07/10Health Care Up On Covid-19 Treatment Developments -- Health Sector Roundup
DJ
07/10WALL STREET STOCK EXCHANGE : Stocks Shrug Off Virus Worries, Log Weekly Gains
DJ
07/10WALL STREET STOCK EXCHANGE : Stocks Poised for Modest Weekly Gains
DJ
07/10WALL STREET STOCK EXCHANGE : Stocks Poised for Modest Weekly Gains
DJ
07/10NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/10WALL STREET STOCK EXCHANGE : Stocks Poised for Modest Weekly Gains
DJ
07/10NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/10WALL STREET STOCK EXCHANGE : Stocks Wobble as Investors Seek Shelter In Bonds
DJ
07/10NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/10NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/07U.S. government awards Novavax $1.6 billion for coronavirus vaccine
RE
More news
News in other languages on BIONTECH SE
07:32aFDA genehmigt beschleunigtes Zulassungsverfahren für Corona-Impfstoffe
07:28aPfizer, BioNTech's Covid-19 Vaccine Candidates Get Fast-Track Designation
07:23aPfizer, BioNTech's coronavirus vaccine candidates get FDA's 'fast track' stat..
06:54aPfizer, BioNTech's coronavirus vaccines get FDA's 'fast track' status
06:46aPfizer and BioNTech Granted FDA Fast Track Designation for Two Investigationa..
More news
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 49,00 €
Last Close Price 62,29 €
Spread / Highest target 1,21%
Spread / Average Target -21,3%
Spread / Lowest Target -43,3%
EPS Revisions
Managers
NameTitle
Ugur Sahin Chief Executive Officer
Helmut Jeggle Chairman-Supervisory Board
Sierk Pötting Chief Operating & Financial Officer
Özlem Türeci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE107.67%15 956
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955